The development of highly effective and durable vaccines against the human malaria
parasites Plasmodium falciparum and P. vivax remains a key priority. Decades of endeavor …

Abstract Development of a malaria vaccine remains a critical priority to decrease clinical
disease and mortality and facilitate eradication. Accordingly, RTS, S, a protein-subunit …

An effective vaccine is needed for the prevention and elimination of malaria. The only
immunogens that have been shown to have a protective efficacy of more than 90% against …

Plasmodium parasites are the causative agent of human malaria, and the development of a
highly effective vaccine against infection, disease and transmission remains a key priority. It …

Abstract Immunization with Plasmodium falciparum (Pf) sporozoites under
chemoprophylaxis (PfSPZ-CVac) is the most efficacious approach to malaria vaccination …

Despite recent advances in treatment and vector control, malaria is still a leading cause of
death, emphasizing the need for an effective vaccine. The malaria life cycle can be …

Background The circumsporozoite protein (CSP) of Plasmodium is a key surface antigen
that induces antibodies and T-cells, conferring immune protection in animal models and …

Vaccines against parasites have lagged centuries behind those against viral and bacterial
infections, despite the devastating morbidity and widespread effects of parasitic diseases …

Introduction Eradication of malaria remains one of the main aims of medicine. Despite
progress in malaria treatment, mortality rate remains high, especially in the poorest parts of …

Recent studies have shown that immune responses against the cell-traversal protein for
Plasmodium ookinetes and sporozoites (CelTOS) can inhibit parasite infection. While these …